Rapsyn facilitates recovery from desensitization in fetal and adult acetylcholine receptors expressed in a muscle cell line. by Cetin, Hakan et al.
J Physiol 00.0 (2019) pp 1–13 1
Th
e
Jo
u
rn
al
o
f
Ph
ys
io
lo
g
y
Rapsyn facilitates recovery from desensitization in fetal
and adult acetylcholine receptors expressed in a muscle
cell line
Hakan Cetin1,2 , Wei Liu1, Jonathan Cheung1, Judith Cossins1, An Vanhaesebrouck1, Susan Maxwell1,
Angela Vincent1,∗, David Beeson1,∗ and Richard Webster1,∗
1Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
2Department of Neurology, Medical University of Vienna, Vienna, Austria
Edited by: Ian Forsythe & Gregory Funk
Key points
 The physiological significance of the developmental switch from fetal to adult acetylcholine
receptors in muscle (AChRs) and the functional impact of AChR clustering by rapsyn are not
well studied.
 Using patch clamp experiments, we show that recovery from desensitization is faster in the
adult AChR isoform.
 Recovery fromdesensitization isdeterminedby theAChR isoform-specific cytoplasmicM3–M4
domain.
 The co-expression of rapsyn in muscle cells induced AChR clustering and facilitated recovery
from desensitization in both fetal and adult AChRs. In fetal AChRs, facilitation of recovery
kinetics by rapsyn was independent of AChR clustering.
 These effects could be crucial adaptations to motor neuron firing rates, which, in rodents,
have been shown to increase around the time of birth when AChRs cluster at the developing
neuromuscular junctions.
Abstract The neuromuscular junction (NMJ) is the site of a number of autoimmune and genetic
disorders, many involving the muscle-type nicotinic acetylcholine receptor (AChR), although
there are aspects of normal NMJ development and function that need to be better understood. In
particular, there are still questions regarding the implications of the developmental switch from
fetal to adult AChRs, as well as how their functions might be modified by rapsyn that clusters the
AChRs.DesensitizationofhumanmuscleAChRswas investigatedusing thepatch clamp technique
to measure whole-cell currents in muscle-type (TE671/CN21) and non-muscle (HEK293) cell
lines expressing either fetal or adult AChRs. Desensitization time constants were similar with
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both AChR isoforms but recovery time constants were shorter in cells expressing adult compared
to fetal AChRs (P < 0.0001). Chimeric experiments showed that recovery from desensitization
was determined by the M3–M4 cytoplasmic loops of the γ- and ε-subunits. Expression of rapsyn
in TE671/CN21 cells induced AChR aggregation and also, surprisingly, shortened recovery time
constants in both fetal and adult AChRs. However, this was not dependent on clustering because
rapsyn also facilitated recovery from desensitization in HEK293 cells expressing a δ-R375HAChR
mutant that did not form clusters in C2C12myotubes. Thus, rapsyn interactions with AChRs lead
not only to clustering, but also to a clustering independent faster recovery from desensitization.
Both effects of rapsyn could be a necessary adjustment to the motor neuron firing rates that
increase around the time of birth.
(Resubmitted 3 May 2019; accepted after revision 3 June 2019; first published online 3 June 2019)
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Introduction
The muscle-type nicotinic acetylcholine receptor in
muscle (AChR) forms a heteropentameric ion channel
and is composed of two α-, one β-, one δ- and one
γ-subunit in fetal muscle, which is replaced by one
ε-subunit in adult muscle. Fetal AChRs are aggregated
into pre-clusters along themuscle fibre before innervation
but, on innervation, become clustered at the post-
synaptic membrane (Braithwaite & Harris, 1979), which
is dependent on the agrin/LRP4/MuSK/DOK7/rapsyn
pathway (Tintignac et al. 2015). At the same time,
γ-subunit mRNA is repressed and replaced by ε-subunit
mRNA transcribed from subsynaptic nuclei (Brenner et al.
1990; Croxen et al. 2001). In human muscle, the switch
from fetal to adult AChRs is largely completed in the third
trimester of gestation (Hesselmans et al. 1993), although
fetal AChRs continue to be expressed at low levels in adult
muscle (MacLennan et al. 1997). By contrast, in mice,
the switch from fetal to adult AChR mRNA expression
takes place postnatally and appears to be complete within
2 weeks with no easily detectable γ-subunit expression in
adult muscle (Sakmann & Brenner, 1978).
Fetal and adult AChRs differ in various functional
aspects. It is already known that the fetal isoform has
a longer mean open time and a lower conductance
compared to the adult receptor (Mishina et al. 1986) and
that agonist affinities are higher in fetal AChRs (Nayak
et al. 2014). It has also been suggested that the higher
affinity of the fetal AChR for choline, together with the
longer mean open time, results in substantially larger
responses of fetal AChRs in prenatal stages, when choline
is present at higher serum concentration levels than in
adults (Nayak et al. 2014). Previous data ondesensitization
and recovery from desensitization show that both depend
on phosphorylation of the M3–M4 cytoplasmic loop of
various AChR subunits (Huganir et al. 1986; Middleton
et al. 1986; Hopfield et al. 1988; Paradiso & Brehm, 1998),
although there is varying evidence for a difference in
desensitization and recovery kinetics between the two
isoforms (Auerbach&Akk, 1998; Paradiso&Brehm, 1998;
Jahn et al. 2001; Krampfl et al. 2002).
The interaction of AChRs with other proteins and
between AChR pentamers in the process of clustering
could also influence desensitization and recovery kinetics.
Rapsyn is a 43 kDa membrane-associated cytoplasmic
protein colocalized with AChRs at the neuromuscular
junction (NMJ) and shown to interact with the M3–M4
cytoplasmic loops of all AChR subunits (Maimone &
Merlie, 1993; Huebsch & Maimone, 2003) via up to three
bridges, which is the minimum number required to form
a 2-D network (Zuber & Unwin, 2013). A coiled-coil
domain encompassing the rapsyn amino acid sequence
298–331 was shown to be crucial for AChR clustering
(Ramarao & Cohen, 1998).
To explore the potential role of rapsyn or receptor
clustering on AChR function, we used the whole-cell,
patch clamp technique and studied desensitization and
recovery from desensitization in human fetal and adult
AChRsexpressed inbothmuscle andnon-muscle cell lines.
Chimeric AChRs with exchanged M3–M4 cytoplasmic
loops between the γ- and ε-subunit were constructed
to address the role of the cytoplasmic domain on
desensitization and recovery kinetics, and rapsyn was
co-expressed in the muscle cell lines to determine to what
extent AChR clustering modifies fetal and adult AChR
functions.
Methods
Cell cultures
TE671 is a rhabdomyosarcoma cell line with muscle-like
properties (Stratton et al. 1989). CN21 cells derive
from the TE671 cell line and have been stably trans-
fected with the cDNA of the human AChR ε-subunit,
such that the adult AChR isoform is expressed in high
numbers with only a remaining small fraction of fetal
AChRs (Beeson et al. 1996). TE671 and CN21 were
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cultured at 37°C and 5% CO2 in Dulbecco-modified
essential medium (DMEM) (Sigma-Aldrich, St Louis,
MO, USA) supplemented with 10% fetal calf serum
(FCS) and 1% antibiotics/anti-mycotics [i.e. penicillin
G, streptomycin and amphotericin B (PSA)] (Invitrogen,
Carlsbad, CA, USA). HEK293 cells were maintained
at 37°C and 5% CO2 in DMEM supplemented with
10% FCS and 1% PSA. C2C12 were maintained at
37°C and 5% CO2 in DMEM supplemented with 15%
fetal calf serum and 1% antibiotics/anti-mycotics and
differentiated to form myotubes for 4–7 days in DMEM
supplementedwith2%fetal calf serumand1%antibiotics/
anti-mycotics.
Plasmids and constructs
Complementary DNAs encoding human AChR α- (P3A
negative isoform), β-, δ-, γ- and ε-subunits were cloned
into pcDNA3.1-hygro. Complementary DNA encoding
human rapsyn (transcript: ENST00000298854.6) was
cloned into pIRES2-EGFP enabling the simultaneous
expression of rapsyn and EGFP (pIRES2-RAPSN-EGFP).
Chimeric subunits were engineered using the
QuickChange Multi Site-Directed Mutagenesis Kit
(Agilent Technologies Inc., Santa Clara, CA, USA).
Restriction enzymes were purchased from New England
Biolabs (Beverly, MA, USA). A BsrGI restriction site was
cloned into the 5′-end of γ- and ε-M3–M4 cytoplasmic
loops using the primers 5′-TGTGGTTGTGCTCAATGT
ACACTTGCGGTCTCCACAC-3′ and 5′-GCGTCATCGT
GCTCAATGTACACCAGCGGACGCCCAC-3′, respecti-
vely, and anAgeI restriction site was cloned into the 3′-end
of γ- and ε-M3–M4 cytoplasmic loops using the primers
5′-GGGCCGAGTGCTGGACCGGTTCTGCTTCCTGGC
CATG-3′ and 5′-TGGGGAATGCCCTTGACCGGTTCTG
CTTCTGGGCCGC-3′, respectively. Then, using BsrGI
andAgeI, the 145 amino acids long γ-M3–M4 cytoplasmic
loop was cloned into the ε-subunit and the 128 amino
acids long ε-M3–M4 cytoplasmic loopwas cloned into the
γ-subunit. BsrGI and AgeI restriction sites were mutated
back using primers 5′-CTGTGGTTGTGCTCAATGTCT
CCCAGCGGACGCCCAC-3′ and 5′-GGGAATGCCCTT
GACAACGTCTGCTTCCTGGCCATGC-3′ for the chim-
eric γ-subunit, and primers 5′-TGCGTCATCGTGCTC
AACGTGTCCTTGCGGTCTCCAC-3′ and 5′-GGCCGA
GTGCTGGACCGCATCTGCTTCTGGGCCGCTC-3′ for
the chimeric ε-subunit. Complementary DNA encoding
the human δ-subunit (transcript: ENST00000298854.6)
was cloned into pBABE-puro and δ-R375H (numbering
according to the mature polypeptide without the signal
sequence) was generated by site-directed mutagenesis
using QuickChange (Stratagene, La Jolla, CA, USA).
Complementary DNAs were Sanger sequenced following
mutagenesis to confirm the presence of exchanged
M3–M4 cytoplasmic loops or of the mutated residue and
the absence of additional variants.
Transfections
To express AChR isoforms inHEK293, cells were seeded at
106 cells per well in six-well plates. At 60–80% confluence
the next day, cells were exposed to a mix of 3 μg of cDNA,
20% glucose and PEI in 2 ml of growth medium. Human
muscle AChR α-, β-, δ- and either γ-subunit cDNA were
used for fetal AChR expression (HEK293-γ) or ε-subunit
cDNA for adult AChR expression (HEK293-ε). Cells were
co-transfectedwith pEGFP-N1 (Invitrogen, Carlsbad, CA,
USA), which contains cDNA encoding EGFP, or with
pEGFP-RAPSN for the co-expression of EGFP-tagged
rapsyn. After 5–7 h of exposure, HEK293 were detached
from the plates using trypsin/EDTA, centrifuged at 1200 g
for 4min, resuspended in growthmediumandplated onto
poly-L-lysine-coated glass coverslips.
To express rapsyn in TE671/CN21, cells were seeded
at 2 × 105 cells per well in six-well plates. The
next day, cells were detached from the plates using
trypsin/EDTA, centrifuged at 1200 g for 4 min and
resuspended in pre-warmed growth medium without
PSA. A corresponding amount of the cell suspension
containing 1.25× 106 cells was again centrifuged at 1200 g
for 5 min and resuspended in 250 μL of resuspension
buffer R containing 20 μg of DNA at a concentration
of 1 μg μL–1. Cells were electroporated with either
pIRES2-EGFP (‘no rapsyn’) or pIRES2-RAPSN-EGFP
(‘with rapsyn’) at 1100 V and a pulse width of 30 ms using
the NEON transfection system (MPK 5000; Invitrogen).
To increase AChR expression levels, another group of
TE671 and CN21 was additionally transfected with cDNA
encoding fetal and adult AChR subunits, respectively.
Immediately after electroporation, cells were resuspended
in pre-warmed growth medium without PSA and plated
onto poly-L-lysine-coated glass coverslips. The medium
was replaced by growth medium with PSA the next day.
Generation of CHRND-knockout (KO) C2C12 cells
CHRND-KO cells were generated using the
CRISPR-Cas9n system (Ran et al. 2013). To introduce
loss-of-function mutations in the CHRND of C2C12
cells (i.e. a mouse muscle cell line) (Yaffe & Saxel, 1977),
10 μg of the CRISPR plasmid containing the guides A
and B was electroporated into C2C12 myoblasts without
the repair template to promote spontaneous in-dels that
would cause a frameshift in the δ-subunit transcript.
Myoblasts of 12 clones were differentiated into myotubes
for agrin-induced AChR clustering to preliminarily
identify clones that do not form AChR clusters. The
clone KO6 was identified to differentiate into myotubes
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without forming AChR clusters after incubation with a
1:100 dilution of medium harbouring full-length human
agrin and was thus chosen for further experiments.
Sequencing of the genomic PCR product of KO6 (a single
band at 750 bp on agarose electrophoresis) identified
three variants for CHRND: two different 13 bp deletions
c.del1136 1148TGTTTGAGAAGCA (c.del1136 1148)
andc.del1131 1143CCTCATGTTTGAG(c.del1131 1143)
and a 25 bp deletion c.del1132 1156CTCATGTTTGA
GAAGCAATCAGAGC (c.del1132 1156). The three
different variants of CHRND identified in the cell line
KO6 most probably derived from the polyploidy nucleus
frequently observed in C2C12 (Burattini et al. 2004).
All three variants cause a frameshift and lead to 31, 28
and 33 missense amino acids, respectively, followed by a
premature stop codon. The variants lead to the loss of
the entire M4 transmembrane domain and result in a
non-functional δ-subunit.
AChR clustering assay
C2C12 were differentiated to myotubes by growth factor
depletion. C2C12 myotubes were incubated for 16 h with
full-length human agrin diluted 1:100 in differentiation
medium. AChR clusters were stained with Alexa Fluor R©
594 conjugated α-bungarotoxin (catalogue no. B13423;
Invitrogen) diluted in 1:1000 in differentiation medium
to a final concentration of 1 μg mL–1 for 60 min at 37°C
and 5.5% CO2. They were then washed 3 × 5 min with
differentiation medium and fixed for 20 min with 3%
paraformaldehyde at room temperature in the dark. Myo-
tubes were washed with PBS and stored in PBS at 4°C.
Quantification of AChR clusters formed on C2C12
myotubes
Images used for the quantification of AChR
clusters labelled with Alexa Fluor R© 594 conjugated
α-bungarotoxin (Invitrogen) on cultured C2C12 myo-
tubes were acquired at 20× magnification using an IX71
fluorescence microscope (Olympus, Tokyo, Japan) with
SimplePCI software (Digital Pixel, Brighton, UK). The
number, length, average area and total area of AChR
clusters larger than 2.5μm2 per field were quantified by
Fiji macro analysis (NIH, Bethesda, MD, USA).
Fluorescence and confocal microscopy
Microscopy was performed on a LSM 880 confocal
microscope (Carl Zeiss, Oberkochen, Germany). Between
2 or 3 days after transfection, cells were incubated
with mAb C7 (Jacobson et al. 1999) for 1 h at room
temperature, which binds the extracellular domain of
the AChR δ-subunit, diluted 1:1000 in staining medium
(DMEM containing 20 mM Hepes and 1% BSA),
before being washed three times with staining medium.
Cells were fixed with 3% paraformaldehyde at room
temperature for 10 min, washed three times with PBS
and incubated with secondary antibody Alexa Fluor R©
594 goat anti-mouse IgG (H+L) (catalogue no. A11005;
Invitrogen; RRID:AB_141372) diluted 1:750 in staining
medium. Cells were washed three times in PBS and
mounted in fluorescence mounting medium (Dako Cyto-
mation, Glostrup, Denmark). Images were captured using
the ZEN System imaging software (Carl Zeiss).
Cell-surface 125I-α-bungarotoxin binding assay
The levels of AChRs on the surfaces of cells cultured in
6-well plates were measured by the 125I-α-bungarotoxin
(125I-α-BuTx) binding assay. For transfected HEK293
cells, the assay was performed on cells 48 h after trans-
fection. To ensure the reproducibility of results, each assay
analysed duplicate wells of cells for each condition. In
the assay, each well was washed three times with PBS,
followed by incubations with 500 μL of 125I-α-BuTx
at 106 cpm mL–1 diluted in blocking solution (DMEM
containing 20 mM Hepes and 1% bovine serum albumin,
BSA) for 1 h at room temperature with gentle rocking.
Subsequently, the cells were washed 3 × 5 min each with
1 mL of PBS and then dissolved in 500 μL of protein
extraction buffer. The cell extracts were transferred to an
Eppendorf tube and the amounts of 125I-α-BuTx bound
were quantified by a gamma-counter. Untransfected
HEK293 cells were used for the estimation of the back-
ground level of radioactivity, which was subtracted from
the cell-surface 125I-α-BuTx binding in transfected cells to
calculate AChR expression levels.
Electrophysiology
Both TE671/CN21 and HEK293 were patched between
2 or 3 days after transfection. All experiments were
performed at room temperature using the whole-cell,
patch clamp configuration. Recording pipettes were made
of thin-walled borosilicate glass (GC150TF-10; Harvard
Apparatus, Cambridge, MA, USA). Pipette tips were
fire-polished to a final resistance of 3 M (MF-900
Microforge; Narishige, London, UK). Extracellular
solutions contained (inmM): 150NaCl, 2.8 KCl, 10Hepes,
2 MgCl2, 2 CaCl2 and 10 glucose with pH adjusted to
7.4 using NaOH. Pipette solutions contained (in mM):
4 NaCl, 144 KCl, 10 Hepes, 2 MgCl2, 2 ATP and 10 EGTA
with pH adjusted to 7.2 using KOH. All measurements
were performed at a holding potential of −60 mV.
Currents were amplified using an Axopatch-1D amplifier
(Molecular Devices, Sunnyvale, CA, USA) and, after
filtering at 5 kHz, sampled to hard disk at 25 kHz. Series
resistance was either corrected using the amplifier-based
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compensation circuit during the recording or a post-
eriori by a software-based computational algorithm as
implemented in ChannelLab (Synaptosoft Inc., Fort Lee,
NJ, USA) (Traynelis, 1998). Residual holding potential
errors were <2 mV.
Fast solution exchange was accomplished using the
modified HSSE-2/3 application system (ALA Scientific
Instruments, Farmingdale, NY, USA). A two-barrel
perfusion pipette with a tip diameter of 300 μm was
used to switch between control and test solutions, both
of which consisted of an agonist containing solution for
receptor stimulation (extracellular solution with 1 mM
ACh) and an agonist-free solution for agonist removal
(extracellular solution). Application times were fast with
10–90% rise times <1 ms in open pipette experiments
and 10–90% current rise times <10 ms in the whole-cell
configuration.
Analysis of desensitization and recovery from
desensitization
Receptor stimulation protocols included ten sweeps of 25 s
in duration, each of which consisted of two consecutive
ACh pulses. A ‘desensitizing’ pulse of 3 s in duration was
followed by a 50 ms ‘test’ pulse. The interval between
pulses increased with each sweep from 300 ms to 7 s
until full recovery from desensitization (Fig. 1A and
B). Desensitization was analysed by fitting one or two
exponential components to the currentdecayphaseduring
the application of the desensitizing pulse. For better
comparison of desensitization between groups, weighted
current decay time constants were calculated according
to: (τ1 × A1 + τ2 × A2)/(A1 × A2), where τx is the
decay time constant for a particular component of the
curve and Ax is the amplitude of the corresponding
component. Recovery from desensitization was analysed
as the ratio between peak current amplitudes of the test
and desensitizing pulse in ten sweeps plotted against the
interval between desensitizing and test pulse. Recovery
time constants were determined by fitting one or two
exponential components to the data points. Clampfit,
version 10.5 (Molecular Devices) or Prism, version 7.0a
(GraphPad Software Inc., San Diego, CA, USA) were used
for exponential curve fitting and current decay or recovery
time constant calculation, respectively.
Statistical analysis
Detailed experimental designs of both immuno-
fluorescence and electrophysiological data are provided
in the Results, including the number of cells used in the
experiments. All data were analysed using Prism, version
7.0a (GraphPad Software Inc.). The results are reported
as the mean ± SEM and compared using a two-tailed
unpaired t test. The degrees of freedom are stated for each
test.
Results
Desensitization is not different between fetal and
adult AChRs but recovery from desensitization is
faster in adult AChRs
First, we used the TE671 and CN21muscle-type cell lines;
the TE671 cells are derived from a rhabdomyosarcoma
and only express the fetal AChR isoform (Stratton
et al. 1989). The CN21 cells were derived from the
TE671 cells by permanent introduction of the gene for
the ε-subunit so that they predominantly express adult
AChRs (Beeson et al. 1996). We then compared the
results with those in the human non-muscle embryonic
kidney cells (HEK293), in which we expressed the two
AChR isoforms independently. Whole-cell currents were
recorded from both muscle-type and non-muscle cells
expressing fetal and adultAChRson their surface (Fig. 1A).
Desensitization was assessed by the calculation of current
decay time constants during a 3 s pulse of 1 mM ACh, a
period sufficient to enable almost completedesensitization
[desensitized current fraction of 93.0 ± 1.3% in TE671
(n = 20), 93.1 ± 1.8% in CN21 (n = 20), 94.4 ± 1.2%
in HEK293-γ (n = 30) and 93.0 ± 1.4% in HEK293-ε
(n = 30)]. Current decay was fitted best by the sum of
two exponentials and weighted time constants were not
significantly different between fetal and adult AChRs in
either cell line (TE671/CN21: t38 = 1.34, P = 0.1899;
HEK293: t58 = 0.18, P = 0.8604) (Fig. 1C and D).
Recovery from desensitization was measured as the
ratio between peak current amplitudes of the test and
desensitizing pulse in ten sweeps with increasing inter-
vals ranging from 300 ms to 7 s, a period after which the
majority of receptors had recovered from desensitization
[87.7 ± 1.2% in TE671 (n = 20), 93.4 ± 0.7% in CN21
(n= 20), 91.6± 0.8 in HEK293-γ (n= 30) and 93.1± 0.7
in HEK293-ε (n = 30)]. Recovery ratio plots could be
fitted best by a single exponential that resulted in shorter
recovery time constants in adult compared to fetal AChRs
in both the muscle-type (t38 = 4.04, P = 0.0003) and
non-muscle cell lines (t58 = 5.96, P < 0.0001) (Fig. 1B, E
and F). In two CN21 cells, recovery from desensitization
was markedly fast (Fig. 1E). After exclusion of these
outliers, the mean recovery time constant remained faster
in adult compared to fetal AChRs (t36 = 3.63, P= 0.0009).
Recovery from desensitization is determined by the
AChR isoform-specific M3–M4 cytoplasmic loop
The cytoplasmic loops between the M3 and M4 trans-
membrane domains of γ- and ε-subunits differ by
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94/146 amino acids. We constructed chimeric AChRs
with exchanged M3–M4 loops between γ- and ε-subunits
(Fig. 2A) and expressed them in HEK293 cells. Current
decay time constants were not different between chimeric
receptors (t18 = 0.37, P = 0.7154) (Fig. 2B), although
recovery from desensitization was faster in chimeric
fetal AChRs/ε-M3–M4 loop than in chimeric adult
AChRs/γ-M3–M4 loop (t18 = 2.35, P= 0.0301) (Fig. 2C).
In chimeric fetal AChRs with the ε-M3–M4 loop, there
were two outliers with markedly faster recovery time
constants. After exclusion of these two cells, the mean
recovery time constant remained faster in chimeric fetal
AChRs but the difference to chimeric adult AChRs was
no longer significant (t16 = 1.64, P = 0.1215). However,
because therewasnoobvious explanation for themarkedly
faster recovery from desensitization in the two cells, they
were not excluded from the analysis. Thus, the ε-subunit
M3–M4 loop transferred fast recovery to the fetal AChR
and the γ-subunit M3–M4 loop transferred slow recovery
to the adult AChR.
Figure 1. Desensitization and recovery kinetics in fetal and adult AChRs
A, receptor stimulation protocol including ten sweeps of 25 s in duration, each of which consisted of two
consecutive ACh pulses of 1 mM concentration. A desensitizing pulse of 3 s in duration was followed by a 50 ms
test pulse after an increasing interval with each sweep. B, averaged recordings from three HEK293 cells expressing
fetal AChRs (black trace) and three HEK293 cells expressing adult AChRs (red trace). For better comparison, traces
were normalized to the peak current amplitude of the desensitizing pulse in the corresponding first sweep. Ten
sweeps are overlaid displaying similar current decay between fetal and adult AChRs and faster recovery from
desensitization in adult AChRs. C, in the muscle-type cell line, mean weighted current decay time constants were
407 ± 62 ms in TE671 (n = 20) and 299 ± 52 ms in CN21 (n = 20). D, in the non-muscle cell line, mean
weighted current decay time constants were 248 ± 33 ms in HEK293-γ (n = 30) and 240 ± 31 ms in HEK293-ε
(n = 30). E, in the muscle-type cell line, mean recovery time constants were 2297 ± 197 ms in TE671 (n = 20) and
1417 ± 93 ms in CN21 (n = 20). In two CN21 cells, recovery from desensitization was markedly fast (E). Neither
the presence, nor the absence of these two cells made a difference to the statistical significance (mean recovery
time constant of 1500 ± 75 ms in CN21 (n = 18), P = 0.0009 after exclusion of outliers). F, in the non-muscle cell
line, mean recovery time constants were 2093 ± 142 ms in HEK293-γ (n = 30) and 1097 ± 88 ms in HEK293-ε
(n = 30). Data represent the mean ± SEM.
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Rapsyn induces AChR aggregation and facilitates
recovery from desensitization of endogenous fetal
and adult AChRs
Immunofluorescence staining of TE671/CN21
muscle-type cell lines confirmed rapsyn-induced
AChR aggregation (Fig. 3A), although the level of AChR
aggregation was low, probably as a result of lower AChR
expression levels in TE671/CN21 cells compared to trans-
fected HEK293 cells. After increasing AChR expression
levels in TE671/CN21 by additional transfection with
cDNA of all of the corresponding AChR isoform subunits
(TE671 + fetal AChRs and CN21 + adult AChRs,
respectively), the level of AChR aggregation also increased
and helped to distinguish cells with and without rapsyn
visually (Fig. 3B). As a result of the heterogeneity and
small size of the AChR aggregates ranging between 0.2
and 0.5 μm, their quantification by Fiji macro analysis
was not feasible.
In whole-cell patch clamp experiments, current decay
was not significantly different after transfection with
human rapsyn cDNA in either TE671 cells (t18 = 0.50,
P = 0.6232) or CN21 cells (t18 = 1.62, P = 0.1226)
(Fig. 3C). Recovery from desensitization, by contrast, was
significantly faster in TE671 (t18 = 3.70, P = 0.0016)
and CN21 cells (t18 = 3.66, P = 0.0018) co-transfected
with rapsyn cDNA (Fig. 3D). In both groups, recovery
ratio plots could be fitted best by a single exponential.
Thus, rapsyn facilitates not only receptor aggregation but
also recovery from desensitization in muscle-type cells
expressing AChRs.
Rapsyn can facilitate AChR recovery kinetics in a
non-clustering AChR mutant
The facilitation of AChR recovery kinetics by rapsyn could
be mediated by the interaction of rapsyn with individual
subunits of the receptor or depend on AChR clustering.
To attempt to distinguish these possibilities, we took
advantage of a naturally occurring congenital myasthenic
syndrome (CMS) mutation (δ-R375H), located in the
M3–M4 cytoplasmic loop of the δ-subunit.
Figure 2. Chimeric AChRs with exchanged M3–M4 cytoplasmic loops between γ- and ε-subunits
A, chimeric γ -subunits (blue) with ε-M3–M4 cytoplasmic loop (orange) and chimeric ε-subunits (orange) with
γ -M3–M4 cytoplasmic loop (blue). Both M3–M4 loops differ at 94/146 positions. A, mean weighted current decay
time constants were 265 ± 72 ms in chimeric fetal (n = 10) and 237 ± 23 ms in chimeric adult (n = 10) AChRs.
C, mean recovery time constants were 1419 ± 174 ms in chimeric fetal (n = 10) and 2022 ± 188 ms in chimeric
adult (n = 10) AChRs. In two cells expressing chimeric fetal AChRs, recovery from desensitization was markedly
faster. After exclusion of these two cells, the mean recovery time constant remained faster in chimeric fetal AChRs
(1634 ± 121 ms, n = 8), although the difference compared to chimeric adult AChRs was no longer significant
(t16 = 1.64, P = 0.1215). There was no obvious explanation for the markedly faster recovery from desensitization
in the two cells in (C). Data represent the mean ± SEM.
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The impact of δ-R375H on AChR clustering was
analysed in C2C12 myotubes (a mouse muscle cell
line expressing fetal AChRs) after knocking-out the
mouse CHRND gene that codes for the AChR
δ-subunit (C2C12δ-KO) using CRISPR-Cas9 technology
and then transfecting C2C12δ-KO with either human δ-WT
(C2C12δ-WT) or human δ-R375H cDNA (C2C12δ-R375H).
Human agrin was applied to compare AChR clustering
between C2C12δ-WT and C2C12δ-R375H. The presence of
the δ-R375Hwas associated withmarkedly reduced AChR
cluster numbers (t4 = 6.71, P = 0.0026), similar to those
found in C2C12δ-KO (Fig. 4A–C).
The impact of the δ-R375HonAChR surface expression
was tested by transfection of cDNAs encoding the
corresponding human AChR subunits into HEK293 cells
and counting AChR-binding of radioactive 125I-α-BuTx.
Surface expression of HEK293δ-R375H was robust and
similar to HEK293δ-WT (t4 = 0.10, P = 0.9244)
(Fig. 4D). To assess the co-localization of rapsyn with
AChRs, HEK293 cells expressing human fetal AChRs
(HEK293-γ) were co-transfected with pEGFP-RAPSN for
the expression of EGFP-tagged rapsyn. This resulted in
clearly discernible AChR aggregation in HEK293-γδ-WT
co-transfectedwith rapsyn (Fig. 4E, upper right), whereas,
in HEK293-γδ-R375H, AChR distribution was less clearly
aggregated after the co-transfection with rapsyn (Fig. 4E,
lower right). The AChR aggregates in HEK293 cells were
generally smaller and appeared as rudimentary forms of
the large AChR clusters in C2C12 myotubes. However,
rapsyn was still found to co-localize with AChRs in
HEK293-γδ-R375H, even in the absence of clear AChR
aggregates (Fig. 4E, lower right), suggesting a direct inter-
action between rapsyn and the mutant AChR. It was thus
concluded that the reduction of AChR cluster numbers
in C2C12 was a result of the inability of mutant AChRs
to produce well-formed clusters rather than resulting
from reduced surface expression of mutant AChRs or
from the inability of mutant AChRs to interact with
rapsyn.
We then tested recovery from desensitization
in HEK293 cells expressing fetal AChRs including
either the WT (HEK293-γδ-WT) or mutant δ-subunits
(HEK293-γδ-R375H) co-transfected with rapsyn cDNA.
Surprisingly, recovery time constants were shorter
irrespective of the clustered state of the AChRs (δ-WT:
t18 = 3.46, P = 0.0028; δ-R375H: t18 = 2.85, P = 0.0107)
(Fig. 4F and G). Thus, facilitation of AChR recovery
kinetics by rapsyn does not depend on receptor clustering
but, instead, on the simple interaction of the receptor with
rapsyn.
Figure 3. Effect of rapsyn on desensitization and recovery kinetics in fetal and adult AChRs
A, in TE671/CN21 cells, the co-transfection of rapsyn cDNA was associated with AChR aggregation on the cell
surface. Scale bar = 10 μm. B, the number and size of AChR aggregates increased after additional transfection
of TE671 and CN21 with the corresponding AChR isoform subunits. Scale bar = 10 μm. C, rapsyn had no effect
on desensitization in TE671 and CN21. Mean weighted current decay time constants were 646 ± 56 ms without
rapsyn (n = 10) and 600 ± 73 ms with rapsyn (n = 10) in TE671, and 464 ± 61 ms without rapsyn (n = 10) and
627 ± 80 ms with rapsyn (n = 10) in CN21. D, recovery from desensitization was faster in both TE671 and CN21
with rapsyn. Mean recovery time constants were 2289 ± 234 ms without rapsyn (n = 10) and 1368 ± 85 ms with
rapsyn (n = 10) in TE671, and 1584 ± 128 ms without rapsyn (n = 10) and 1014 ± 89 ms with rapsyn (n = 10)
in CN21. Data represent the mean ± SEM.
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Discussion
The existence of subtle differences in structure and
pharmacology of fetal and adult AChRs at mammalian
NMJs was established in the 1970s (Green et al.
1975), although the functional implications are still
not yet fully understood despite the increasing number
of recognized disorders of neuromuscular transmission
(Cetin & Vincent, 2018; Rodriguez Cruz et al. 2018). We
compared desensitization and recovery kinetics between
human fetal and adult AChRs expressed in muscle-type
and non-muscle cell lines using whole-cell patch clamp
recordings and an optimized perfusion system, which
enabled direct and accurate comparisons. Desensitization
did not differ between the two isoforms but recovery
from desensitization was faster in the adult AChR and
dependent on the isoform-specific M3–M4 cytoplasmic
loop, suggesting a role for phosphorylation. Nevertheless,
rapsyn co-expression facilitated recovery kinetics of both
isoforms and, unexpectedly, this effect was independent
of AChR clustering.
Desensitization of the nicotinic AChR at the NMJ
was described over 60 years ago and shown to occur
within seconds of agonist application and to recover
within seconds of agonist removal (Katz & Thesleff,
1957). More recent studies characterized desensitization
in fetal and adult AChRs with time constants ranging
from tens of milliseconds (Paradiso & Brehm, 1998;
Figure 4. Functional impact of rapsyn on AChR function in the absence of AChR clustering
A, comparison of C2C12 myotubes expressing wild-type AChRs or AChRs bearing the δ-R375H. The mutation was
associated with the failure of the AChRs to cluster. Scale bar = 100 μm. B, mean cluster numbers were 75.3 ± 10.5
per vision field in C2C12δ-WT (n = 3) and 4.4 ± 1.2 per vision field in C2C12δ-R375H (n = 3). In C2C12δ-KO, the
mean cluster number per vision field was 3.2 ± 2.1 (n = 3). C, there was no statistically significant difference in
the size of remaining clusters in C2C12δ-R375H (7.0 ± 1.9 μm2, n = 3) and C2C12δ-WT (10.1 ± 2.0 μm2, n = 3). D,
surface expression of AChRδ-R375H was robust and similar to AChRδ-WT when tested in HEK293 cells [125I-α-BuTx
binding of 9882 ± 143 cpm in HEK293δ-R375H (n = 3) and 9847 ± 312 cpm in HEK293δ-WT (n = 3)]. E, by contrast
to HEK293-γ δ-WT co-transfected with rapsyn, where AChR aggregates were clearly visible (upper right), AChR
aggregation was inconsistent in HEK293-γ δ-R375H despite the co-localization of rapsyn with AChRδ-R375H (lower
right). Scale bar = 10 μm. Recovery from desensitization was analysed in HEK293 expressing wild-type (F) or
mutant AChRs (G). In both, the co-transfection of rapsyn cDNA was associated with significantly faster recovery
kinetics. In HEK293-γ δ-WT, mean recovery time constants were 1799 ± 176 ms without rapsyn (n = 10) and
1037 ± 132 ms with rapsyn (n = 10). In HEK293-γ δ-R375H, mean recovery time constants were 1541 ± 95 ms
without rapsyn (n = 10) and 1085 ± 129 ms with rapsyn (n = 10). Data represent the mean ± SEM.
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Jahn et al. 2001; Krampfl et al. 2002) to several seconds
(Hopfield et al. 1988; Wagoner & Pallotta, 1988) or even
minutes (Chesnut, 1983). Desensitization is a function
of agonist concentration (Dilger & Liu, 1992) and
these differences may have resulted from varying agonist
concentrations used in different studies. Phosphorylation
of the M3–M4 cytoplasmic AChR loop has also been
shown to affect desensitization and recovery from
desensitization (Huganir et al. 1986; Hopfield et al. 1988;
Hoffman et al.1994;Paradiso&Brehm,1998). It is possible
that post-translational AChR modification influenced
desensitizationor different applications of the patch clamp
technique could have contributed to the differences found
in previous studies (Auerbach & Akk, 1998). In the
present study, we attempted to avoid these possibilities
by using the whole-cell method and making direct
comparisons between fetal and adult AChRs expressed
in both muscle-type (TE671/CN21) and non-muscle
(HEK293) cells, in which desensitization was found to be
similar in fetal and adult AChRs. However, desensitization
time constants tended to be slower in the muscle-type
cell line compared to non-muscle cells. Differences in
post-translationalAChRmodificationor the interactionof
AChRs with other proteins (Burden et al. 2018) differently
expressed in the two cell lines could have contributed
to the observed variations in TE671/CN21 and HEK293
cells. Consequently, TE671/CN21 cells were used in
experiments with respect to the effect of rapsyn on AChR
function to ensure a more physiological intracellular
environment for AChRs. C2C12 myotubes are capable
of producing well-formed AChR clusters upon agrin
stimulation and thus may qualify as an even better model
for experiments on many aspects of muscle function,
but their utilization for measurements of recovery from
desensitization by whole-cell patch clamping is associated
with various methodological problems as a result of the
large cell size and large current amplitudes (Traynelis,
1998; Fu et al. 2011). Moreover, the study of mutant
AChRs or proteins involved in AChR clustering is limited
by the endogenous expression of the wild-type form of
those proteins in C2C12 myotubes. In our experiments
on chimeric AChRs and the δ-R375H mutation, we
thus used HEK293 cells that do not express wild-type
AChRs, the presence of which would have made the
findings uninterpretable. As a limitation, there are obvious
differences in AChR clustering between the three cell lines
utilized in our experiments, which might compromise the
comparability of some of the results. The most obvious
explanation for these variations is the lack of themolecular
machinery in TE671/CN21 andHEK293 cells required for
full AChR clustering. However, there can be little doubt
from the evidence obtained here that the co-transfection
with rapsyn is at least sufficient to form rudimentary
AChR aggregates, which differ functionally from AChRs
without rapsyn. Evidence also derives from experiments
on myasthenia gravis, in which some previously AChR
antibody negative sera were shown to contain IgG anti-
bodies that bound AChRs expressed on a cell surface
only when co-transfected with rapsyn (Leite et al. 2008;
Rodriguez Cruz et al. 2015); this is now used as a clinical
assay in several laboratories.
To our knowledge, no previous studies have investigated
the consequences of clustering on AChR function,
which is an essential characteristic of the normal NMJ.
Intriguingly, rapsyn co-transfection intobothmuscle-type
and non-muscle cell lines, which induced clearly visible
aggregates on the surface of the cells, facilitated recovery
kinetics of both fetal and adult AChRs. More surprising,
however, was that rapsyn increased recovery rates even in
AChRs that were unable to cluster in C2C12 myotubes
because of a mutation in the delta-subunit (δ-R375H),
suggesting a direct effect of rapsyn on AChR function
independent of receptor clustering. Alternatively, AChRs
harbouring the δ-R375H mutation could have aggregated
into mini-clusters of reduced size not visible by micro-
scopy but sufficient to facilitate AChR recovery from
desensitization.
The small AChR aggregates in HEK293 cells were
clearly different compared to the large AChR clusters
in C2C12 myotubes and might thus represent different
structural modifications of the AChR surface distribution.
One potential explanation for the variation of AChR
aggregation and clustering between both cell lines is the
lack of the molecular machinery in HEK293 cells that is
required for full AChR clustering. It is also important
to appreciate that the effect of rapsyn on HEK293 or
TE671/CN21 cells cannot be considered identical to the
effects in C2C12 myotubes or even at the NMJ. The
relatively small size of these cells ranging between 10
and 20 μm would probably not accommodate AChR
clusters of around 10 μm typically seen in C2C12 myo-
tubes and certainly not a full-sized mature NMJ of up to
30μminhumanmuscle. Because the interactions between
AChRs and rapsyn do not form the typical AChR clusters
described in C2C12 myotubes, we refer to these as AChR
aggregates rather than clusters. However, our finding of
allosteric modulation of AChR function by its interaction
with rapsyn is interesting and may also be relevant for
other proteins expressed at the NMJ, which were shown to
directly interact with the AChR. These include Src-family
kinases (Fuhrer and Hall, 1996), the tumour suppressor
protein adenomatous polyposis coli (Wang et al. 2003)
and caveolin-3 (Hezel et al. 2010).
The physiological significance of desensitization and
recovery from desensitization at the NMJ is disputed
(Giniatullin et al. 2005). Desensitization is a slow process
compared to the lifetime of ACh in the synaptic cleft that
ranges between 200 and 500 μs (Smart & McCammon,
1998) as a result of hydrolysis by the enzyme acetylcholine
esterase (AChE). Therefore, desensitization might not
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have a significant impact on shaping endplate currents in
muscle. However, desensitization might become relevant
at highly active synapses. Motor neuron firing rates
are extremely low, around 0.5 Hz, in mice at birth
when fibres are still multiply innervated but, from the
second week, there is an increase of motor neuron firing
frequencies to levels usually found in adult mice (Vrbova
et al. 1985; Personius & Balice-Gordon, 2001). These
high motor neuron firing rates, however, can overcome
the catalytic AChE capacity and increase the lifetime
of ACh in the synaptic cleft sufficiently to desensitize
AChRs (Magleby & Pallotta, 1981; Ruzzier & Scuka, 1986;
Giniatullin et al. 1993; Giniatullin et al. 1997), leading
to a progressive reduction in endplate currents. In this
context, the developmental switch to the ε-subunit with
faster recovery kinetics, which occurs around the same
time as the change in motor neuron firing rates, could
provide an adaptation to increasing motor neuron firing
rates after birth, facilitating the robust and reproducible
high-frequent neuromuscular transmission in the adult.
The effects of rapsyn on recovery times, as well as the
switch from fetal to adult AChRs, would be important to
help maintain a sufficient number of activatable receptors
between stimuli at high frequent firing rates.
These results have potential clinical relevance.
Rapsyn-induced clustering of AChRs is the result of
a highly regulated pathway initiated by nerve-released
agrin, interacting with LRP4 and stimulating MuSK and
DOK7 phosphorylation, which then leads eventually to
rapsyn and AChR clusters. There are a number of genetic
disorders of the neuromuscular junction (CMS), many of
which are caused by mutations in the AChR, rapsyn or
DOK7 but associated variably with extraocular muscle
weakness. Extraocular muscles have exceptionally high
motor neuron firing frequencies in the range of several
hundred hertz (Yu Wai Man et al. 2005), which therefore
require fast AChR recovery rates for efficient neuro-
muscular transmission. In patients with null mutations
of the CHRNE gene (coding for the ε-subunit) (Ealing
et al. 2002; Engel et al. 2015), neuromuscular trans-
mission has to depend on the fetal AChR, and one major
symptomatic feature of these patients is ophthalmoplegia.
Rapsyn-induced clustering of the fetal form and its
effect on recovery from desensitization could be crucial
with respect to allowing a number of these patients to
have some, albeit impaired, extraocular muscle function.
Further investigation of the role of rapsyn could help in
understanding better the pathophysiology of these very
heterogeneous and interesting synaptic disorders.
In conclusion, our findings provide important
justifications for the significance of the developmental
switch from fetal to adult AChRs around the time of birth,
and they are also relevant to patients with CMS where
there is complete loss of adult AChRs and where low levels
of fetal AChR expression are sustained in mature muscle.
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